RNAi INHIBITION OF SERUM AMYLOID FOR TREATING GLAUCOMA

• Main Authors: WANG WAN-HENG, MCNATT LORETTA, CLARK ABBOTT F
• Format: Patent
• Language: English; Japanese
• Published: 12.03.2015
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide an interfering RNA that targets mRNA of SAA to interfere with expression of SAA mRNA.SOLUTION: Provided is RNA interference to inhibit the expression of serum amyloid A (SAA) mRNA in glaucoma involving SAA expression. Also provided is a method for attenuating expression of SAA mRNA in an eye of a subject, which method comprises a step of administering a composition comprising an effective amount of interfering RNA having a length of 19-49 nucleotides and a pharmaceutically acceptable carrier to the eye of the subject, where the interfering RNA comprises a sense nucleotide sequence, an antisense nucleotide sequence and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides between the sense and antisense sequences. 【課題】ＳＡＡのｍＲＮＡを標的にし、それによってＳＡＡのｍＲＮＡの発現を干渉する干渉ＲＮＡの提供。【解決手段】ＳＡＡの発現を伴う緑内障における血清アミロイドＡ ｍＲＮＡの発現を阻害するためのＲＮＡ干渉が提供される。対象の眼において血清アミロイドＡ ｍＲＮＡの発現を弱める方法であって、１９〜４９ヌクレオチドの長さを有する干渉ＲＮＡの有効量および薬学的に許容可能な担体を含む組成物を該対象の眼に投与する工程を包含し；該干渉ＲＮＡが、センスヌクレオチド配列、アンチセンスヌクレオチド配列、および該センス配列と該アンチセンス配列との間の少なくともほぼ完全に連続して相補性の少なくとも１９ヌクレオチドの領域を含む方法もまた提供される。【選択図】図３